Navigation Links
Medifast to Exceed Revenue Guidance for 2008
Date:12/16/2008

curities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend" or other similar words or the negative of such terminology. Similarly, descriptions of Medifast's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Medifast believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Medifast's inability to attract and retain independent Associates and Members, stability in the pricing of print, TV and Direct Mail marketing initiatives affecting the cost to acquire customers, increases in competition, litigation, regulatory changes, and its planned growth into new domestic and international markets and new channels of distribution. Although Medifast believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.


    Contact:  Brendan Connors
              Vice President - Finance
              ir@choosemedifast.com

              Lytham Partners, LLC
              Joe Diaz
              Robert B
'/>"/>
SOURCE Medifast, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Medifast Diversified Business Model Drives Strong Revenue and Earnings Growth for the Third Quarter of 2008
2. Medifast Adds New Crunchy Bars to Product Line
3. Medifast, Inc. to Announce Third Quarter of Fiscal Year 2008 Financial Results on Thursday, November 6, 2008
4. Medifast Announces Opening of First Franchise Clinic
5. Medifast Challenging Dieters to Express Your Success in Video Contest
6. Medifast Announces Second Quarter 2008 Financial Results
7. Medifast Program Combined with Appetite Suppressants Proven to Yield Double the Weight Loss Compared to Suppressants Alone
8. Medifast Weight Control Centers to Open in California
9. Medifast, Inc. to Present at the Canaccord Adams Diabetes & Obesity Conference
10. Medifast, Inc. Names Barry B. Bondroff, CPA to Board of Directors
11. Medifast Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, ... common antidepressant can quickly alter the way brain cells communicate ... online Sept. 18 in Current Biology , are ... prescribed antidepressants. Experts said the hope is to eventually be ... benefit from a drug -- and which people would fare ...
(Date:9/18/2014)... true: exercise is good for you. But new research ... have an added benefit for cancer patients undergoing chemotherapy. ... melanoma, found that combining exercise with chemotherapy shrunk tumors ... associate professor in the School of Nursing and director ... was the senior author on the study, which appears ...
(Date:9/18/2014)... Texas (PRWEB) September 19, 2014 ... Inside the Neighborhood Mission (Misión Barrio Adentro), ... of the healthcare system (see Section 6.1.3.). ... billion) in an Autonomous Service of Pharmaceutical ... production plant, which provides medicines at a ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Thousands of ... be recognizing their shared fundraising impact on 127 member ... 25. , The first-ever Dance Marathon Day will officially ... million projected to be raised by college and high ... Hospital. Donations generated through Dance Marathon campus programs help ...
(Date:9/18/2014)... 18, 2014 Ben Quirk, CEO of ... Jr. Leadership Award by the Savannah Science Seminar in ... wellness throughout the nation and especially in Savannah. , ... said Ben. “The Savannah Science Seminar is an amazing ... multiple generations have gone through the program,” he added. ...
Breaking Medicine News(10 mins):Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2
... arms to snip away tumors , TUESDAY, Dec. 18 ... promise in the removal of cancer involving the tonsils, ... University of Pennsylvania, the transoral robotic surgery (TORS) system ... with an endoscope, an optical instrument with two video ...
... in the December issue of The Journal of the ... cancer operations in 80-year-olds are considerably worse than reported ... lead to unrealistic expectations about the safety of these ... patients and their physicians may have difficulty accurately assessing ...
... Calif., Dec. 18 BioMarin,Pharmaceutical Inc. (Nasdaq and ... Canadian rights for tetrahydrobiopterin (BH4), including,Kuvan(TM) (sapropterin dihydrochloride), ... Germany. Kuvan is an oral small molecule for ... Merck,Serono. Based on published literature, there are approximately ...
... 18 Art Mellor is one of,more than 400,000 ... from,Multiple Sclerosis (MS). It,s, a debilitating disease that causes,paralysis, ... no wonder that Mellor, the founder of the Accelerated,Cure ... and more,interested in raising the funds he needs to ...
... Southwestern Medical Center researchers have found that the existing body ... of obese patients at risk of cardiovascular disease. , ... Surgery for Obesity and Related Diseases, is among ... index (BMI) and cardiovascular disease as it relates to bariatric ...
... and Implantability Characteristics, MINNEAPOLIS, Dec. 18 ... manufacturer and marketer of state-of-the-art cardiac,surgery products ... Drug,Administration (FDA) approval for the ATS Open ... http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ), The ATS AP360 heart ...
Cached Medicine News:Health News:Robotic Surgery Treats Tonsil Cancer 2Health News:Study finds outcomes of high-risk cancer operations in 80-year-olds worse than reported 2Health News:BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono 2Health News:BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono 3Health News:BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono 4Health News:This Holiday Season Some Dream of a White Christmas - The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 2Health News:This Holiday Season Some Dream of a White Christmas - The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 3Health News:BMI criteria for obesity surgery should be lowered, UT Southwestern researchers suggest 2Health News:ATS Medical Receives FDA Approval for AP360 Mechanical Heart Valve 2Health News:ATS Medical Receives FDA Approval for AP360 Mechanical Heart Valve 3
(Date:9/18/2014)... Australia , Sept. 18, 2014 Veterinary ... of Dr. Ashraf Hanna , M.D., Ph.D., and ... Board of Directors. Dr. Hanna is the Vice President ... Chief Financial Officer for the Genentech Foundation, while Dr. ... Head of Business Development and Licensing for Roche Pharma. ...
(Date:9/18/2014)... 18, 2014  Spring Bank Pharmaceuticals, Inc., a ... treatment of RNA viruses, today announced a research ... for animal testing of the Company,s lead compound, ... "Special Pathogens," against which currently there are no ... Spring Bank,s proprietary Small Molecule Nucleic Acid ...
(Date:9/18/2014)...   Auxilium Pharmaceuticals, Inc. (NASDAQ: ... announced the first presentation of positive safety and ... Investigation of Collagenase Optimizing the Resolution of Dupuytrens) ... histolyticum (CCH) for the treatment of two Dupuytren,s ... the study examined expanded flexibility with timing of ...
Breaking Medicine Technology:Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 2Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 3Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 4Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 5Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 6Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 7
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
... Cobalt Binding (ACB®) Test is a clinical ... (IMA®) by measuring the cobalt binding capacity ... First identified in the early 1990s, IMA ... contact with ischemic tissue in the heart. ...
Inquire...
Medicine Products: